Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Lixte Biotechnology Holdings ( (LIXT) ) is now available.
On December 17, 2025, Lixte Biotechnology Holdings amended its collaborative study agreement with GSK and The University of Texas MD Anderson Cancer Center to expand an ongoing clinical trial combining its PP2A inhibitor LB-100 with GSK’s dostarlimab in ovarian clear cell carcinoma, doubling the planned enrollment from 21 to 42 patients and increasing the supply of study drugs, while GSK’s financial commitments remain tied to the original cohort size. Concurrently, Lixte entered a separate collaborative research agreement under which MD Anderson will conduct the expanded study at its own cost in exchange for up to $1.5 million in milestone payments tied to future regulatory and clinical developments in clear cell ovarian cancer and a 3.75% royalty on net profit from LB-100 or related products in this indication, with trial sites at MD Anderson and Northwestern having already reached the initial 21-patient target and Lixte indicating on December 23, 2025, that data from this first cohort are expected to be presented in 2026, underscoring the strategic importance of LB-100 in the company’s oncology pipeline and its deepening ties with major academic and pharmaceutical partners.
More about Lixte Biotechnology Holdings
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies based on novel biological targets. Its lead product candidate, LB-100, is a first-in-class PP2A inhibitor that has shown tolerability at doses associated with anti-cancer activity and is being evaluated in proof-of-concept clinical trials for ovarian clear cell carcinoma and metastatic colon cancer, with a market focus on enhancing the effectiveness of existing chemo- and immunotherapies.
Average Trading Volume: 107,599
Technical Sentiment Signal: Hold
Current Market Cap: $27.09M
See more data about LIXT stock on TipRanks’ Stock Analysis page.